Immunic (IMUX) Total Non-Current Liabilities (2013 - 2026)
Immunic (IMUX) reported Total Non-Current Liabilities of $146000.0 for Q1 2026, down 30.48% on a YoY basis from $210000.0 in Q1 2025, and up 36.45% sequentially from $107000.0 in Q4 2025.
Immunic (IMUX) Total Non-Current Liabilities (2013 - 2026) Analysis & Trends
Immunic (IMUX) has 14 years of Total Non-Current Liabilities data on file, last reported at $146000.0 in Q1 2026.
- For the quarter ending Q1 2026, Total Non-Current Liabilities fell 30.48% year-over-year to $146000.0; the trailing twelve-month figure through Mar 2026 stood at $146000.0 (down 30.48% YoY), and the FY2025 full-year result was $107000.0, down 59.47% from the prior year.
- Total Non-Current Liabilities climbed to $146000.0 in Q1 2026, from $107000.0 in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $1.4 million in Q1 2023 to a low of $107000.0 in Q4 2025.
- A 5-year average of $504235.3 and a median of $407000.0 in 2022 frame the typical range for Total Non-Current Liabilities.
- Across the five-year window, Total Non-Current Liabilities soared 198.28% in 2023 and slumped 80.15% in 2024, its largest moves.
- Tracing IMUX's Total Non-Current Liabilities over 5 years: stood at $992000.0 in 2022, then sank by 35.58% to $639000.0 in 2023, then slumped by 58.69% to $264000.0 in 2024, then sank by 59.47% to $107000.0 in 2025, then surged by 36.45% to $146000.0 in 2026.
- Business Quant data shows IMUX's Total Non-Current Liabilities at $146000.0 in Q1 2026, $107000.0 in Q4 2025, and $126000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 4.45 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 110.28 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.98 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 949,738.67 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 5.87 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 7.32 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 40.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 746.94 Mn |
| 10 | Immunic | 11.03 Mn | 11.03 Mn | - | 146,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 146,000.00 |
| Dec 31, 2025 | 107,000.00 |
| Sep 30, 2025 | 126,000.00 |
| Jun 30, 2025 | 205,000.00 |
| Mar 31, 2025 | 210,000.00 |
| Dec 31, 2024 | 264,000.00 |
| Sep 30, 2024 | 186,000.00 |
| Jun 30, 2024 | 241,000.00 |
| Mar 31, 2024 | 433,000.00 |
| Dec 31, 2023 | 639,000.00 |
| Sep 30, 2023 | 789,000.00 |
| Jun 30, 2023 | 1.21 Mn |
| Mar 31, 2023 | 1.35 Mn |
| Dec 31, 2022 | 992,000.00 |
| Sep 30, 2022 | 759,000.00 |
| Jun 30, 2022 | 407,000.00 |
| Mar 31, 2022 | 502,000.00 |
| Dec 31, 2021 | 584,000.00 |
| Sep 30, 2021 | 701,000.00 |
| Jun 30, 2021 | 829,000.00 |